Table 2 Baseline characteristics of enrolled patients
From: Non-target embolic events during prostatic embolization with ethylene vinyl alcohol copolymer (EVOH)
Patients n | 10 |
|---|---|
Age (Mean ± SD) | 72.6 (63–82) SD 5.6 |
Urologic medical history, n (%) | |
Yes | 1 (1%)a |
No | 9 (9%) |
Cardiovascular medical history, n (%) | 6 (6%) |
High blood pressure/diabetes | 4 (4%) |
Smoking | 4 (4%) |
Dyslipidaemia | 4 (4%) |
Anticoagulant ± Antiplatelet therapy, n (%) | 6 (6%) |
IPSS (Mean ± SD) | 18.7 (8–32) SD 7.6 |
QoL (Mean ± SD) | 5.3 (3–6) SD 1 |
Medication(s) for BPH n (%)b | 10 (100%) |
Prostate Volume, mL (Mean ± SD) | 84 (50–170) SD 40 |
PSA, ng/mL (Mean ± SD) | 3.94 (1–15) SD 3.9 |
Age (Mean ± SD) | 72.6 ± 5.6 |
Urologic medical history, n (%) | |
Yes | 1 (1%) |
No | 9 (9%) |
Cardiovascular medical history, n (%) | 6 (6%) |
High blood pressure/diabetes | 4 (4%) |
Smoking | 4 (4%) |
Dyslipidaemia | 4 (4%) |
Anticoagulant ± Antiplatelet therapy, n (%) | 6 (6%) |
IPSS Mean ± SD | 18.7 ± 7.6 |
QoL Mean ± SD | 5.3 ± 1 |
Medication for BPH n (%) | 10 (100%) |
Prostatic volume Mean ± SD | 84 ± 40 mL |
PSA Mean ± SD | 3.94 ± 3.9 ng/mL |